# Inhaled mRNA Tumor-associated Antigen Dry Powder Vaccine in Advanced Lung Cancer and Lung Metastasis of Solid Tumors.

> **NCT06928922** · EARLY_PHASE1 · RECRUITING · sponsor: **Cancer Institute and Hospital, Chinese Academy of Medical Sciences** · enrollment: 83 (estimated)

## Conditions studied

- Advanced Lung Cancer
- Lung Metastasis

## Interventions

- **BIOLOGICAL:** BMD006 monotreatment
- **BIOLOGICAL:** BMD006 in combination with PD-1 antibody
- **BIOLOGICAL:** BMD006 in combination with PD-1/VEGF antibody

## Key facts

- **NCT ID:** NCT06928922
- **Lead sponsor:** Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-02-24
- **Primary completion:** 2027-02-24
- **Final completion:** 2028-02-24
- **Target enrollment:** 83 (ESTIMATED)
- **Last updated:** 2026-01-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06928922

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06928922, "Inhaled mRNA Tumor-associated Antigen Dry Powder Vaccine in Advanced Lung Cancer and Lung Metastasis of Solid Tumors.". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT06928922. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*